Trials / Withdrawn
WithdrawnNCT01833767
Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma
Phase 2 Trial of T-cell Based Low-dose Cyclophosphamide and Outpatient Intravenous Interleukin-2 in Metastatic Melanoma
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Western Regional Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine response rates by administering low dose cyclophosphamide on day 1, followed by 5 days of outpatient IL2.
Detailed description
To determine the response rate, median duration of response and median survival of patients treated with this low-dose cyclophosphamide + moderate dose bolus Interleukin-2 schedule.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cyclophosphamide and Interleukin 2 | Cytoxan IV day 1, IL2 IV days 1-5 |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2013-04-17
- Last updated
- 2017-08-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01833767. Inclusion in this directory is not an endorsement.